View:
Download DOC
Download PDF
Download XLS
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
BIOGEN IDEC INC
(Last) (First) (Middle)
14 CAMBRIDGE CENTER
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TARGETED GENETICS CORP /WA/ [ TGEN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/06/2002
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.01 Par Value 09/30/2002 J 104,854(1) A $0.55 9,400,516 I By Biogen Idec MA, Inc.(2)
Common Stock, $0.01 Par Value 11/06/2002 J 210,819(3) D $1.07 9,611,335 I By Biogen Idec MA, Inc.(2)
Common Stock, $0.01 Par Value 08/15/2003 P 2,515,843(4) A $1.91 12,127,178 I By Biogen Idec MA, Inc.(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
BIOGEN IDEC INC
(Last) (First) (Middle)
14 CAMBRIDGE CENTER
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
1. Name and Address of Reporting Person*
BIOGEN IDEC MA INC
(Last) (First) (Middle)
14 CAMBRIDGE CENTER
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
Explanation of Responses:
1. The reporting person received these shares as additional merger consideration for its preferred shares of Genovo, Inc. exchanged in the merger of a subsidiary of Targeted Genetics Corporation with and into Genovo on September 19, 2000, pursuant to the exercise of the Genzyme Corporation's stock option in connection with the merger.
2. Shares are owned indirectly by Biogen Idec Inc. and directly by its wholly-owned subsidiary Biogen Idec MA, Inc., fka Biogen, Inc.
3. The reporting person forfeited these shares on 11/6/2002 to Targeted Genetics in connection with certain of its indemnification claims under the Agreement and Plan of Merger, dated August 8, 2000, among Genovo, Inc., Targeted Genetics, a wholly-owned subsidiary of Targeted Genetics and the reporting person, a stockholder of Genovo.
4. The reporting person purchased these shares on 8/15/2003 upon exercise by Targeted Genetics of its right to put such shares to the reporting person for purchase under the Funding Agreement dated as of August 8, 2000 between Targeted Genetics and the reporting person.
Remarks:
Exhibit List Exhibit 99- Joint Filer Information
/s/ Raymond G. Arner, Acting General Counsel 07/12/2005
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                                                         Exhibit 99

            Form 4 Joint Filer Information


Name:  				Biogen Idec MA, Inc.

Address:			14 Cambridge Center
				Cambridge, Massachusetts 02142

Designated Filer:		Biogen Idec Inc.

Issuer and Ticker Symbol:	Targeted Genetics Corporation (TGEN)

Date of Earliest
Transaction Required
to be Reported:			September 30, 2002


Signature:			By:   	/s/ Michael Phelps
				Name:  	Michael Phelps
				Title:  Treasurer